SpyGlass Pharma (SGP)

• Market cap: $791M
• 1 day: -9.91%
• 5 days: -12.17%
• 1 month: -18.95%
• 3 months: -10.08%
• 6 months: -10.08%
• Year to date: -10.08%
• 1 year: -10.08%
• 5 years: -10.08%
• 10 years: -10.08%
• Sector: Healthcare
• Industry: Biotechnology

About: SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.